Cantor Fitzgerald Keeps Their Buy Rating on Cybin (CYBN)
In a report released today, Pete Stavropoulos from Cantor Fitzgerald reiterated a Buy rating on Cybin. The company’s shares opened today at $6.17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Stavropoulos is a 3-star analyst with an average return of 9.3% and a 40.74% success rate. Stavropoulos covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Vera Therapeutics, and Rezolute.
Currently, the analyst consensus on Cybin is a Strong Buy with an average price target of $86.33.
CYBN market cap is currently $1.4M and has a P/E ratio of -1.34.
Read More on CYBN:
Disclaimer & DisclosureReport an Issue
- Cybin Advances Clinical Programs in Psychedelic Therapeutics
- Cybin Inc. Strengthens U.S. Market Position with New SEC Filing
- Cybin Inc. Announces CEO Transition as of September 2, 2025
- Cybin’s Promising Clinical Advancements and Strategic Positioning Justify Buy Rating
- Psychedelic: Cybin completes enrollment in CYB004 Phase 2 study
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.